As AtheroGenics prepares to wrap up phase 3 trial sites for its lead atherosclerosis compound, small molecule AGI-1067, the future could suddenly become very bright for this tiny research company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results